iodixanol


Also found in: Wikipedia.

i·o·dix·an·ol

(ī'ō-diks'ă-nol),
5,5'-[(2-hydroxy-1,3-propane)bis(acetylamino)]bis[N,N'-bis(2,3- dihydroxypropyl)-2,4,6- triiodo-1,3-benzenedicarboxamide]; a dimeric, nonionic, low osmolar, water-soluble radiographic contrast medium for intravascular use.
References in periodicals archive ?
Iodixanol Peripheral Computer Tomographic Angiography Study Investigator Panel.
into practice after iodixanol contrast other recent medium could be studies.
A novel contrast-induced acute kidney injury model based on the 5/6-nephrectomy rat and nephrotoxicological evaluation of iohexol and iodixanol in vivo," Oxidative Medicine and Cellular Longevity, vol.
Methods: In an experimental study 40 adult male Wistar rats were randomly divided into four equal groups including: 1) Control group (No drug), 2) Contrast media group (10 ml/kg iodixanol i.
A double blind comparison of iodixanol and opamidol.
Este metodo emplea un gradiente discontinuo no ionico de iodixanol (OptiPrep-Sigma) y posterior ultrafiltracion por una membrana de 100 kDa para concentrar la muestra y remover el iodixanol.
NICE, FRANCE -- A study of 77,000 Swedish cardiac patients found rates of renal failure were about twice as high following the use of iodixanol, an iso-osmolar contrast medium promoted as less toxic to the kidneys than competing low-osmolar products, Pontus B.
Plasma, either spiked with PbTx-3 or from mice treated for 30 min with PbTx-3, was fractionated into different-sized lipoproteins by iodixanol gradient ultracentrifugation.
7) Iso-osmolar B Varying volumes of iodixanol, an iso-osmolar contast media contrast medium, were used rather than iohexol, a low osmolar contrast medium.
A method for the separation of the predominant LDL subclass with HDL and VLDL on a single-step iodixanol gradient has also been described recently (9).
A first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of GE Healthcare's isosmolar contrast media (CM) iodixanol (Visipaque) and the low-osmolar CM iopromide in select patients concluded iodixanol is associated with lower incidence of contrast-induced neuropathy (CIN) and cardiovascular events (CV) than iopromide, when used in patients with chronic kidney disease.